Halozyme Therapeutics Inc (HALO)

[jamtomorrow2]

This is all one big never ending struggle. HALO never produces any nice surprises. Just consistently disappointing royalties and consistently higher than expected expenses. So much for the interim updates on HALO301. They can't even tell us how many patients have signed up or a likely date for the first interim update. As it's our trial we can say what we like - we just always choose to say nothing. If we ask a question about partners you have to ask the partner. Ask a question about HALO and they refuse to answer. Why do I always think that voluntary silence like this spells bad news? Did Shire ever release the long term Phase 4 study results on HyQvia? I can't seem to find them. Maybe there's something in those that would explain Shire's reluctance to effectively market HyQ or maybe they just like to market there own Cuvitru, which requires way more injections but to hell with the patients if you can save the 5% royalty. And this whole matter of Roche seemingly not seeking approval for SQ Herceptin is bizarre not to mention another example of to hell with the patients. I'm staggered that you Americans put up with it. But HALO doesn't seemingly care - so what if we should have been making another $50m a year selling SQ Herceptin - Roche is the client. I don't know why HALO don't force their hand by threatening to talk to the forthcoming biosimilar Herceptin pharmas. I suppose we can't for contractual reasons - same as we couldn't do other SQ deals on generic Cinryse and Gammagard, both of which are not patent protected. It appears you just pay HALO a few million dollars and you can stop them going to the competition. We are running into this problem too much. We should be making hundreds of millions in royalties by now on Enhanze products but we're not. OK so there's nothing on the horizon now this year except early stage trial results, which based on the recent 4 failures, aren't cast iron certainties.